{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-042966","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.724030+00:00","generated_at":"2026-06-02T00:45:13.741446+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Citius Pharma Q2 net loss $8.5M; LYMPHIR PDUFA Aug 13, Mino-Lok data due Q2","bullets":["Cash $12.6M at Mar 31; $15M April offering extends runway through Dec 2024.","LYMPHIR BLA accepted with PDUFA target date August 13, 2024.","Mino-Lok Phase 3 topline results anticipated in calendar Q2 2024.","Merger of oncology sub with TenX (TENK) progressing; pending SEC/TENK approval.","Net loss $8.5M ($0.05/shr) vs $10.5M loss a year ago; R&D expense down."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-042966","json":"https://secwatch.observer/filing/0001213900-24-042966.json","markdown":"https://secwatch.observer/filing/0001213900-24-042966.md","text":"https://secwatch.observer/filing/0001213900-24-042966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024042966/0001213900-24-042966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024042966/ea0206086-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:45:13.741446+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c3ecc73309e8398177fcd20eb0a42a54b32282ba","claim":"Citius Pharmaceuticals, Inc. reported fiscal second quarter 2024 ended March 31, 2024 results: net income Net loss was $8.5 million and $17.8 million, or ($0.05) and ($0.11) per share for the three and six months ended March 3, EPS ($0.05) and ($0.11) per share for the three and six months ended March 31, 2024.","evidence_excerpt":"Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390024042966/0001213900-24-042966-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal second quarter 2024 ended March 31, 2024"},{"label":"Net income","value":"Net loss was $8.5 million and $17.8 million, or ($0.05) and ($0.11) per share for the three and six months ended March 3"},{"label":"EPS","value":"($0.05) and ($0.11) per share for the three and six months ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}